Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Diverse Behavior in 18F-Fluorocholine PET/CT of Brain Tumors in Patients With Neurofibromatosis Type 1

Pena Pardo, Francisco José MD*; Moreno, José María Borrás MBBS; Jiménez Aragón, Fátima MD; González García, Jesús MBBS§; García Vicente, Ana María MD*

doi: 10.1097/RLU.0000000000002636
Interesting Images
Buy

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that causes CNS tumors in around 20% of patients, being pilocytic astrocytomas (PA), and particularly optic pathway gliomas (OPG), the most common. We present three cases of NF1 patients referred for 18F-fluorocholine PET/CT because of suspected glioma in the setting of ongoing FUMEGA (Functional and Metabolic Glioma Analysis) trial. One case turned out to be a WHO grade I ganglioglioma; the second was a high grade glioma; and the last one (negative in PET) a probable low-grade glioma.

From the *Nuclear Medicine,

Neurosurgery,

Radiology

§Pathology Departments, University General Hospital, Ciudad Real, Spain.

Received for publication November 8, 2018; revision accepted April 14, 2019.

No disclaimer. All the authors have participated in the writing and revision of this article and take public responsibility for its content.

The present publication is approved by all authors and by the responsible authorities where the work was carried out.

All the authors confirm the fact that the article is not under consideration for publication elsewhere.

Compliance with Ethical Standards.

Conflicts of interest and sources of funding: none declared.

Research involving Human Participants and/or Animals: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in the study.

Correspondence to: Francisco José Pena Pardo, MD, Nuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n. 13005, Ciudad Real, Spain. E-mail: fjpena@msn.com.

Online date: June 19, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.